ImmunityBio Stock Rises on Accelerated Approvals from Saudi Regulators for Anktiva Treatment

Dow Jones

昨天

By Kelly Cloonan

Shares of ImmunityBio gained after the company received accelerated approval from Saudi regulators for two indications for its Anktiva treatment.

The stock rose 6.6% to $3.01 on Wednesday. Shares are up 28% in the last 12 months.

The immunotherapy company said it received accelerated approval from the the Saudi Food and Drug Authority for Anktiva to treat non-muscle invasive bladder cancer and metastatic non-small cell lung cancer.

The company also plans to open a regional office in Saudi Arabia to support its expansion in the Middle East and North Africa. It plans to work with Biopharma Cigalah as its commercial and distribution partner in the region.

Bladder and lung cancers have grown more common in the region, posing a need for further treatment options, Chief Executive Rich Adcock said.

"We are pursuing approvals across the region to fill that need," Adcock said.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

January 14, 2026 11:14 ET (16:14 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2603485976"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603485976\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603485976?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-15 00:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603485976","market":"sh","top_or_hot":-1,"title":"ImmunityBio Stock Rises on Accelerated Approvals from Saudi Regulators for Anktiva Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of ImmunityBio gained after the company received accelerated approval from Saudi regulators for two indications for its Anktiva treatment. \n</p>\n<p>\n  The stock rose 6.6% to $3.01 on Wednesday. Shares are up 28% in the last 12 months. \n</p>\n<p>\n  The immunotherapy company said it received accelerated approval from the the Saudi Food and Drug Authority for Anktiva to treat non-muscle invasive bladder cancer and metastatic non-small cell lung cancer. \n</p>\n<p>\n  The company also plans to open a regional office in Saudi Arabia to support its expansion in the Middle East and North Africa. It plans to work with Biopharma Cigalah as its commercial and distribution partner in the region. \n</p>\n<p>\n  Bladder and lung cancers have grown more common in the region, posing a need for further treatment options, Chief Executive Rich Adcock said. \n</p>\n<p>\n  \"We are pursuing approvals across the region to fill that need,\" Adcock said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 14, 2026 11:14 ET (16:14 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmunityBio Stock Rises on Accelerated Approvals from Saudi Regulators for Anktiva Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunityBio Stock Rises on Accelerated Approvals from Saudi Regulators for Anktiva Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-15 00:14</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of ImmunityBio gained after the company received accelerated approval from Saudi regulators for two indications for its Anktiva treatment. \n</p>\n<p>\n  The stock rose 6.6% to $3.01 on Wednesday. Shares are up 28% in the last 12 months. \n</p>\n<p>\n  The immunotherapy company said it received accelerated approval from the the Saudi Food and Drug Authority for Anktiva to treat non-muscle invasive bladder cancer and metastatic non-small cell lung cancer. \n</p>\n<p>\n  The company also plans to open a regional office in Saudi Arabia to support its expansion in the Middle East and North Africa. It plans to work with Biopharma Cigalah as its commercial and distribution partner in the region. \n</p>\n<p>\n  Bladder and lung cancers have grown more common in the region, posing a need for further treatment options, Chief Executive Rich Adcock said. \n</p>\n<p>\n  \"We are pursuing approvals across the region to fill that need,\" Adcock said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 14, 2026 11:14 ET (16:14 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2603485976","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603485976","pubTimestamp":1768407240,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of ImmunityBio gained after the company received accelerated approval from Saudi regulators for two indications for its Anktiva treatment.The stock rose 6.6% to $3.01 on Wednesday. Shares are up 28% in the last 12 months.The immunotherapy company said it received accelerated approval from the the Saudi Food and Drug Authority for Anktiva to treat non-muscle invasive bladder cancer and metastatic non-small cell lung cancer.The company also plans to open a regional office in Saudi Arabia to support its expansion in the Middle East and North Africa. It plans to work with Biopharma Cigalah as its commercial and distribution partner in the region.Bladder and lung cancers have grown more common in the region, posing a need for further treatment options, Chief Executive Rich Adcock said.\"We are pursuing approvals across the region to fill that need,\" Adcock said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IBRX":"ImmunityBio, Inc."},"translate_title":"ImmunityBio股价因沙特监管机构加速批准Anktiva治疗而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":0.9},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Shares of ImmunityBio gained after the company received accelerated approval from Saudi regulators for two indications for its Anktiva treatment. \n\n\n  The stock rose 6.6% to $3.01 on Wednesday. Shares are up 28% in the last 12 months. \n\n\n  The immunotherapy company said it received accelerated approval from the the Saudi Food and Drug Authority for Anktiva to treat non-muscle invasive bladder cancer and metastatic non-small cell lung cancer. \n\n\n  The company also plans to open a regional office in Saudi Arabia to support its expansion in the Middle East and North Africa. It plans to work with Biopharma Cigalah as its commercial and distribution partner in the region. \n\n\n  Bladder and lung cancers have grown more common in the region, posing a need for further treatment options, Chief Executive Rich Adcock said. \n\n\n  \"We are pursuing approvals across the region to fill that need,\" Adcock said. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 14, 2026 11:14 ET (16:14 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}